About
SEC Filings
Back


Form 424B4
FIBROCELL SCIENCE, INC. filed this Form 424B4 on 12/08/2017
Document Outline
Entire Document (481.4 KB)
Subdocument 1 - 424B4 - 424B4
Page 1 - Filed Pursuant to Rule 424(b)(4)
Page 2 - TABLE OF CONTENTS
Page 3 - PROSPECTUS SUMMARY
Page 4 - Intrexon Collaborations
Page 5 - Phase 1/2 Clinical Trial of FCX-007 for RDEB
Page 6 - FCX-013 for Moderate to Severe Localized Scleroderma
Page 7 - New Gene Therapy Program for Arthritis and Related Conditions
Page 8 - Corporate Information
Page 9 - THE OFFERING
Page 10 - Outstanding Shares
Page 11 - N/A
Page 12 - RISK FACTORS
Page 13 - Management will have broad discretion as to the use of the proceeds from this offering, and we may n
Page 14 - There is no public market for the common warrants or the pre-funded warrants in this offering.
Page 15 - SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
Page 16 - N/A
Page 17 - SELECTED FINANCIAL DATA
Page 18 - Fibrocell Science, Inc.
Page 19 - Fibrocell Science, Inc.
Page 20 - USE OF PROCEEDS
Page 21 - MARKET PRICE OF OUR COMMON STOCK
Page 22 - CAPITALIZATION
Page 23 - N/A
Page 24 - DILUTION
Page 25 - N/A
Page 26 - DESCRIPTION OF CAPITAL STOCK
Page 27 - Voluntary Conversions by Holders.
Page 28 - Liquidation Preference.
Page 29 - No Exchange Listing of Preferred Shares.
Page 30 - Preferred Stock
Page 31 - Transfer Agent and Registrar
Page 32 - DESCRIPTION OF SECURITIES WE ARE OFFERING
Page 33 - Cashless Exercise
Page 34 - Pre-Funded Warrants
Page 35 - Fundamental Transactions
Page 36 - CERTAIN RELATIONSHIPS AND TRANSACTIONS WITH RELATED PERSONS
Page 37 - Registration Rights Agreement
Page 38 - PRINCIPAL STOCKHOLDERS
Page 39 - N/A
Page 40 - N/A
Page 41 - N/A
Page 42 - UNDERWRITING
Page 43 - Underwriter Warrants
Page 44 - Right of First Refusal
Page 45 - Indemnification
Page 46 - LEGAL MATTERS
Page 47 - WHERE YOU CAN FIND MORE INFORMATION
Page 48 - 7,714,156 Units



Printer Friendly Version E-mail this page RSS E-mail Alerts Download Financial Tear Sheet